Hepatitis C Global Clinical Trials Review, H2, 2017

  • ID: 4413724
  • Clinical Trials
  • Region: Global
  • 1564 pages
  • GlobalData
1 of 4

FEATURED COMPANIES

  • AbbVie Inc
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences Inc
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Merck & Co Inc
  • MORE
Hepatitis C Global Clinical Trials Review, H2, 2017

Summary

The clinical trial report, “Hepatitis C Global Clinical Trials Review, H2, 2017" provides an overview of Hepatitis C clinical trials scenario. This report provides top line data relating to the clinical trials on Hepatitis C. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). The Clinical Trial Reports are generated using the author’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Scope
  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months
Reasons to buy
  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AbbVie Inc
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences Inc
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Merck & Co Inc
  • MORE
  • Report Guidance
  • Clinical Trials Report Coverage
  • Clinical Trials by Region
  • Clinical Trials and Average Enrollment by Country
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
  • Top Five Countries Contributing to Clinical Trials in Europe
  • Top Countries Contributing to Clinical Trials in North America
  • Top Five Countries Contributing to Clinical Trials in Middle East and Africa
  • Top Five Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Hepatitis C to Infectious Disease Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Hepatitis C to Infectious Disease Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
  • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
  • Top Companies Participating in Hepatitis C Therapeutics Clinical Trials
  • Prominent Drugs
  • Latest Clinical Trials News on Hepatitis C
  • Aug 17, 2017: Gilead Receives Approval in Canada for VOSEVI (Sofosbuvir/Velpatasvir/Voxilaprevir) for Re-treatment of Certain Patients with Chronic Hepatitis C Virus (HCV) Infection
  • Aug 16, 2017: The Lancet Infectious Diseases publishes Phase 3 data showing 99 percent of adults with chronic hepatitis C infection and compensated cirrhosis achieved virologic cure with AbbVie’s glecaprevir/pibrentasvir
  • Aug 15, 2017: Cocrystal Announces Positive Data from the Successful Completion of Phase 1a/1b Trial of the Non-Nucleoside Polymerase Inhibitor CC-31244 for the Treatment of Chronic Hepatitis C Infection
  • Clinical Trial Profile Snapshots
  • Appendix
  • Abbreviations
  • Definitions
  • Research Methodology
  • Secondary Research
  • About
  • Contact
  • Source
List of Tables
  • Hepatitis C Therapeutics, Global, Clinical Trials by Region, 2017*
  • Hepatitis C Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017*
  • Hepatitis C Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017*
  • Hepatitis C Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017*
  • Hepatitis C Therapeutics Clinical Trials, Europe, Top Five Countries, 2017*
  • Hepatitis C Therapeutics Clinical Trials, North America, Top Countries, 2017*
  • Hepatitis C Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2017*
  • Hepatitis C Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2017*
  • Proportion of Hepatitis C to Infectious Disease Clinical Trials, G7 Countries (%), 2017*
  • Hepatitis C Therapeutics, G7 Countries, Clinical Trials by Phase, 2017*
  • Hepatitis C Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017*
  • Proportion of Hepatitis C to Infectious Disease Clinical Trials, E7 Countries (%), 2017*
  • Hepatitis C Therapeutics, E7 Countries, Clinical Trials by Phase, 2017*
  • Hepatitis C Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017*
  • Hepatitis C Therapeutics, Global, Clinical Trials by Phase, 2017*
  • Hepatitis C Therapeutics, Global, Clinical Trials In Progress by Phase 2017*
  • Hepatitis C Therapeutics, Global, Clinical Trials by Trial Status, 2017*
  • Hepatitis C Therapeutics Clinical Trials, Global, by End Point Status, 2017*
  • Hepatitis C Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016
  • Hepatitis C Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017*
  • Hepatitis C Therapeutics Clinical Trials, Global, Key Sponsors, 2017*
  • Hepatitis C Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017*
  • Hepatitis C Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017*
List of Figures
  • Hepatitis C Therapeutics, Global, Clinical Trials by Region (%), 2017*
  • Hepatitis C Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017*
  • Hepatitis C Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017*
  • Hepatitis C Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017*
  • Hepatitis C Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017*
  • Hepatitis C Therapeutics Clinical Trials, North America, Top Countries (%), 2017*
  • Hepatitis C Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2017*
  • Hepatitis C Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2017*
  • Proportion of Hepatitis C to Infectious Disease Clinical Trials, G7 Countries (%), 2017*
  • Hepatitis C Therapeutics, G7 Countries, Clinical Trials by Phase, 2017*
  • Hepatitis C Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017*
  • Proportion of Hepatitis C to Infectious Disease Clinical Trials, E7 Countries (%), 2017*
  • Hepatitis C Therapeutics, E7 Countries, Clinical Trials by Phase, 2017*
  • Hepatitis C Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017*
  • Hepatitis C Therapeutics, Global, Clinical Trials by Phase (%), 2017*
  • Hepatitis C Therapeutics, Global, Clinical Trials In Progress by Phase, 2017*
  • Hepatitis C Therapeutics, Global, Clinical Trials by Trial Status, 2017*
  • Hepatitis C Therapeutics Clinical Trials, Global, by End Point Status, 2017*
  • Hepatitis C Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016
  • Hepatitis C Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017*
  • Hepatitis C Therapeutics Clinical Trials, Global, Key Sponsors, 2017*
  • Hepatitis C Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017*
  • Hepatitis C Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017*
  • Methodology
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Merck & Co Inc
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences Inc
  • Johnson & Johnson
  • AbbVie Inc
  • Bristol-Myers Squibb Company
  • Vertex Pharmaceuticals Inc
  • C. H. Boehringer Sohn AG & Co KG
  • Novartis AG
  • GlaxoSmithKline Plc
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll